#Singapore #Louis Widmer #Hyphens Pharma #Cerapro MED

Hyphens Pharma Expands Reach in Europe with Cerapro® MED

Hyphens Pharma International Limited, a leading specialty pharmaceuticals and consumer healthcare company based in Singapore, has announced an exciting new development in its product licensing strategy. The company has entered into a partnership with Louis Widmer SA, granting them the rights to market the innovative Cerapro® MED Skin Barrier Cream in six European countries including Switzerland, Liechtenstein, Austria, Belgium, Luxembourg, and the Netherlands. This collaboration marks a significant step forward in addressing skin health issues, particularly for those suffering from atopic dermatitis, a common type of eczema affecting millions worldwide.

About Cerapro® MED

Cerapro® is a patented skin cream designed to lower the pH of the skin, effectively treating atopic dermatitis. It has received approval under the stringent European Medical Devices Regulation (CE marking), signifying its credibility as a medical product that offers a novel approach to managing this skin condition. The product excels in restoring the skin barrier function, reducing the elevated pH levels often associated with eczema, and additionally supports the skin's antimicrobial defenses.

This cream’s advanced formulation is particularly crucial as it addresses a core issue in skin health — an impaired skin barrier and altered pH levels. With many patients suffering from these conditions, Cerapro® provides much-needed relief and enhanced health outcomes.

Partnership with Louis Widmer

Louis Widmer, recognized globally as a reputable name in the dermatological product sector, will spearhead the marketing and distribution of Cerapro® in the specified markets. Since its inception in 1960, this Swiss-based company has prided itself on providing high-quality skin care solutions and has established a robust presence among dermatologists and pediatricians. Through this partnership, both companies share a mutual vision of delivering scientifically validated products that improve treatment outcomes for patients.

“Forming this groundbreaking partnership with Louis Widmer reflects our commitment to innovation and patient care,” stated Lim See Wah, Chairman and CEO of Hyphens Pharma. “By leveraging Louis Widmer's strong expertise in dermatology, we aim to make Cerapro® accessible to patients across Europe while continuing to explore new growth opportunities.”

Annemarie Widmer, CEO of Louis Widmer, expressed her enthusiasm about the collaboration: “We are thrilled to partner with Hyphens Pharma to introduce Cerapro® to our markets and provide patients with a clinically proven solution for atopic dermatitis. Cerapro® will be the flagship product of our Remederm line, leading in the care of dry, very dry, and atopic skin within Europe.”

The Broader Vision of Hyphens Pharma

Hyphens Pharma operates with a firm belief that everyone deserves a better quality of life. Based in Singapore, they have a strong operational footprint extending into various regions across Asia, including Malaysia, Vietnam, Indonesia, and the Philippines. Their integrated ecosystem encompasses a medical hypermarket and a digital pharmacy platform, ensuring seamless prescription fulfillment and direct drug delivery to patients, acting as an invaluable resource for healthcare providers.

In addition to Cerapro®, Hyphens Pharma has developed an array of dermatological products and dietary supplements, solidifying its place as a key player in healthcare innovation. As it looks to the future, this strategic alliance with Louis Widmer is expected to drive significant growth while enhancing health and wellness for countless dermatology patients.

For more information about Hyphens Pharma and their product offerings, please visit www.hyphensgroup.com.

For further inquiries, you may contact:
Karina Choo / Gerald Woon / Chong Yi Sze
Email: [email protected]
DID: (65) 6704 9280
Mobile: (65) 9107 6991